NDRA
ENDRA Life Sciences Inc
NASDAQ: NDRA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$4.87
+0.41% today
Updated 2026-04-30
Market cap
$5.98M
P/E ratio
—
P/S ratio
1,838.78x
EPS (TTM)
$-8.93
Dividend yield
—
52W range
$3 – $12
Volume
0.1M
ENDRA Life Sciences Inc (NDRA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $702934.00 | $486722.00 | $490761.00 | $6.12M | $7.22M | $7.18M | $8.76M | $12.87M | $9.27M | $6.75M | $4.45M |
| Cash & equivalents | $156442.00 | $19128.00 | $144953.00 | $5.60M | $6.47M | $6.17M | $7.23M | $9.46M | $4.89M | $2.83M | $3.23M |
| Current assets | $404416.00 | $126618.00 | $195593.00 | $5.88M | $6.95M | $6.54M | $8.21M | $12.09M | $8.53M | $3.03M | $3.43M |
| Total liabilities | $97601.00 | $236422.00 | $1.38M | $848214.00 | $974583.00 | $2.42M | $1.60M | $2.09M | $2.07M | $1.10M | $1.89M |
| Current liabilities | $97601.00 | $236421.00 | $1.38M | $848214.00 | $974583.00 | $2.07M | $986663.00 | $1.54M | $1.70M | $903095.00 | $605230.00 |
| Long-term debt | — | — | — | — | — | — | $337084.00 | $28484.00 | — | — | — |
| Shareholder equity | $605333.00 | $250300.00 | $-893767.00 | $5.28M | $6.25M | $4.76M | $7.17M | $10.78M | $7.20M | $5.66M | $2.56M |
| Retained earnings | $-7.46M | $-9.74M | $-12.52M | $-17.90M | $-27.69M | $-45.22M | $-57.34M | $-68.69M | $-81.87M | $-91.93M | $-103.44M |
| Accounts receivable | — | $0.00 | — | $6850.00 | $145424.00 | $116749.00 | $390800.00 | $-1.35M | — | $-2.62M | — |
| Inventory | $238988.00 | $99004.00 | $40105.00 | $191680.00 | $59444.00 | $113442.00 | $589620.00 | $1.28M | $2.64M | $2.62M | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — |